Unten ist eine Momentaufnahme der Seite angezeigt, wie sie am 10.06.2024 angezeigt wurde (das letzte Datum, an dem unser Crawler sie besucht hat). Es handelt sich um die Version der Seite, die für das Ranking Ihrer Suchergebnisse verwendet wurde. Die Seite hat sich möglicherweise seit der letzten Zwischenspeicherung geändert. Damit Sie sehen können, was sich geändert hat (ohne die Markierungen), navigieren Sie zur aktuellen Seite.
Bing ist nicht für den Inhalt dieser Seite verantwortlich.
Top Pharmaceutical Company - Juniper Biologicswordslines060020top 50%bottom top100.22back10.0011.11.5nonetop bottomcenter centertrue1nonetop topcenter toptrue0200.001none
top bottomtop center true1nonetop bottombottom bottom true1noneSkip to content
Innovative Medicine Made Accessible to Those in Need
Our Story
Latest News
Juniper Biologics Named “Pharmaceutical Company of the Year” at Corporate LiveWire Global Awards USA – English
Advancing Healthcare Innovation: Juniper Biologics Recognized as the Best Novel Therapy R&D and Commercialization Company 2024 by APAC Insider
Juniper Biologics Clinches Prestigious Molecular Science & Technology Acquisition of the Year Award at the Acquisition International M&A Awards 2023
Juniper Therapeutics Acquires Exclusive Rights for SAR Registration for Anti-Viral COVID-19 Drug from Ping An-Shionogi Hong Kong for Singapore
Singapore-based Juniper Biologics Awarded the Most Innovative Oncology Pharmaceutical Company 2023 by GHP Healthcare and Pharmaceutical Awards
JUNIPER BIOLOGICS PARTNERS WITH CARIS LIFE SCIENCES® FOR MOLECULAR PROFILING DISTRIBUTION IN SOUTH EAST ASIA
Acquisition International Magazine’s M&A Award 2022 for Best Cell & Gene Therapy Acquisition 2022
CEO Raman Singh speaks about his mission to bring accessibility to the core of pharmaceutical innovation while being committed to ESG.
Juniper Biologics Establishes Global Headquarters in Singapore
Helsinn Healthcare SA signs exclusive license agreement with Juniper Biologics Pte. Ltd. for LEDAGA® (chlormethine) in Australia, Asia and the Middle East*
Juniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging markets*
Juniper Biologics Acquires Cell-Mediated Gene Therapy TG-C LD For Treatment of Knee Osteoarthritis
Juniper Biologics In-Licenses Helsinn’s Oncology Portfolio For Aloxi®, Onicit®, Paloxi®, Akynzeo® and Anamorelin (INN)
Juniper Biologics Announces the Appointment of Raman Singh as Chief Executive